Harbour BioMed submits IND application for HBM9378/SKB378 to China NMPA to treat chronic obstructive pulmonary disease: Suzhou, China Monday, November 11, 2024, 17:00 Hrs [IST] Ha ...
New Delhi based NGO Udyog Development Foundation (UDF) has called for an experts meeting themed “India Pharmacists' Adhiveshan” towards creation of regulatory service cadre in the pharma sector for ...
Dr Jayachandra Babu Ramapuram has been honoured with the prestigious AAPS Fellow Award at the American Association of Pharmaceutical Scientists (AAPS) annual meeting held in Salt Lake City, Utah. This ...
Leucine Rich Bio, now unveils its #HappyGutMission campaign an initiative designed to educate people on the critical role of gut health. This campaign has brought gut health to the forefront, offering ...
Robles BioCeutics LLC, a regenerative dermatology company, announced a new collaboration with BioCentrium aimed at advancing research into the molecular mechanisms behind its patent-pending Glowselle ...
US FDA advisory panel votes in favour of IceCure's ProSense cryoablation benefit-risk profile in early-stage low risk breast cancer: Caesarea, Israel Monday, November 11, 2024, 15 ...
SystImmune, Inc (SystImmune), a clinical-stage biotechnology company, announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BL-M17D1, ...
EMA's Committee for Veterinary Medicinal Products (CVMP) has issued the first certificate for a vaccine platform technology master file (vPTMF) which will support and accelerate the development and ...
Quantiphi and DDReg partner to transform regulatory reporting in life sciences through AI: Our Bureau, Bengaluru Monday, November 11, 2024, 13:45 Hrs [IST] Quantiphi, a global AI- ...
Johnson & Johnson announced the submission of regulatory applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval of a new indication for Darzalex ...
Exports of Ayush and herbal products for the first six months of the current fiscal has reported a 10.34 per cent growth, as ...
Nammi Therapeutics begins patient dosing in phase 1 study of QXL138AM for advanced solid tumours and multiple myeloma: Los Angeles Monday, November 11, 2024, 13:00 Hrs [IST] Nammi ...